<DOC>
	<DOCNO>NCT02614612</DOCNO>
	<brief_summary>To determine INCB039110 combination corticosteroid safe tolerable patient Grade IIB-IVD acute graft-versus-host disease ( GVHD ) .</brief_summary>
	<brief_title>Study INCB039110 Combination With Corticosteroids Treatment Acute GVHD</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Have undergone first alloHSCT donor source ( match unrelated donor , sibling , haploidentical ) use bone marrow , peripheral blood stem cell , cord blood hematologic malignancy . Recipients nonmyeloablative myeloablative transplant eligible . Clinically suspected Grades IIB IVD acute GVHD per modify MNCIBMTR criterion , occur alloHSCT condition regimen antiGVHD prophylactic program . Subjects may , require , previously receive corticosteroid acute GVHD : Evidence myeloid engraftment . Use growth factor supplementation allow . Has receive 1 hematopoietic stem cell transplantation . Has progress 2 prior treatment regimen acute GVHD . Presence active uncontrolled infection . Subjects relapse primary disease , subject treat relapse allogeneic hematopoietic stemcell transplantation ( alloHSCT ) perform . Inadequate recovery toxicity and/or complication prior alloHSCT . Any corticosteroid therapy ( indication GVHD ) dose &gt; 1 mg/kg per day methylprednisolone equivalent within 7 day randomization . Previously receive JAK inhibitor therapy indication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Acute Graft Versus Host Disease</keyword>
</DOC>